Davies: Approvals from 0 pre-'98; 2011-2016 10 approvals. Targeted Tx BRAF DCR >90%, resp 1y. ImmunoRx: ORR10%-60% resp 2y #AGBT18

12:20pm February 13th 2018 via Hootsuite